IN2015DN03203A - - Google Patents

Info

Publication number
IN2015DN03203A
IN2015DN03203A IN3203DEN2015A IN2015DN03203A IN 2015DN03203 A IN2015DN03203 A IN 2015DN03203A IN 3203DEN2015 A IN3203DEN2015 A IN 3203DEN2015A IN 2015DN03203 A IN2015DN03203 A IN 2015DN03203A
Authority
IN
India
Prior art keywords
binding agent
impurities
mixture
cytotoxic agent
cell
Prior art date
Application number
Other languages
English (en)
Inventor
Xinfang Li
Wenjie Cheng
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of IN2015DN03203A publication Critical patent/IN2015DN03203A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
IN3203DEN2015 2012-10-04 2013-10-04 IN2015DN03203A (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261709871P 2012-10-04 2012-10-04
PCT/US2013/063503 WO2014055893A1 (en) 2012-10-04 2013-10-04 Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates

Publications (1)

Publication Number Publication Date
IN2015DN03203A true IN2015DN03203A (no) 2015-10-02

Family

ID=50435480

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3203DEN2015 IN2015DN03203A (no) 2012-10-04 2013-10-04

Country Status (13)

Country Link
US (1) US20150307596A1 (no)
EP (1) EP2903450A4 (no)
JP (1) JP2015535215A (no)
CN (1) CN105208876A (no)
AU (1) AU2013326897A1 (no)
CA (1) CA2886996A1 (no)
HK (1) HK1213148A1 (no)
IL (1) IL238111A0 (no)
IN (1) IN2015DN03203A (no)
MX (1) MX2015004258A (no)
RU (1) RU2015116883A (no)
SG (1) SG11201502430QA (no)
WO (1) WO2014055893A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282138B2 (en) 2005-08-24 2024-01-01 Immunogen Inc A process for preparing purified drug compounds
BRPI1010620B8 (pt) 2009-06-03 2021-05-25 Immunogen Inc métodos de conjugação
MX369659B (es) 2011-03-29 2019-11-15 Immunogen Inc Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa.
NZ707091A (en) 2012-10-04 2018-12-21 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
GB201616758D0 (en) * 2016-10-03 2016-11-16 Ge Healthcare Bio Sciences Ab Novel chromatography media
CN108549763B (zh) * 2018-04-09 2021-06-01 电子科技大学 一种用于离子推进器数值模拟的电荷交换碰撞mcc方法
CN118290514A (zh) * 2024-06-05 2024-07-05 东曜药业有限公司 基于阴离子膜的抗体偶联药物的纯化方法及抗体偶联药物
CN118290513A (zh) * 2024-06-05 2024-07-05 东曜药业有限公司 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1467758A4 (en) * 2002-01-03 2007-11-14 Smithkline Beecham Corp PREPARATION OF IMMUNOCONJUGATES
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
ES2503719T3 (es) * 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
IL282138B2 (en) * 2005-08-24 2024-01-01 Immunogen Inc A process for preparing purified drug compounds
BRPI1010620B8 (pt) * 2009-06-03 2021-05-25 Immunogen Inc métodos de conjugação
MX369659B (es) * 2011-03-29 2019-11-15 Immunogen Inc Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa.

Also Published As

Publication number Publication date
HK1213148A1 (zh) 2016-06-30
JP2015535215A (ja) 2015-12-10
WO2014055893A1 (en) 2014-04-10
AU2013326897A1 (en) 2015-05-07
SG11201502430QA (en) 2015-04-29
EP2903450A4 (en) 2016-05-11
US20150307596A1 (en) 2015-10-29
IL238111A0 (en) 2015-05-31
CN105208876A (zh) 2015-12-30
RU2015116883A (ru) 2016-11-27
EP2903450A1 (en) 2015-08-12
CA2886996A1 (en) 2014-04-10
MX2015004258A (es) 2015-09-25

Similar Documents

Publication Publication Date Title
IN2015DN03203A (no)
IN2015DN03202A (no)
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
MX2021005426A (es) Ciclodextrina y formulaciones de conjugados anticuerpo-farmaco.
PH12015500243B1 (en) Glycoconjugation processes and compositions
MX2016017355A (es) Lipido que comprende acido docosapentaenoico.
MX2015005792A (es) Compuestos de conjugado antisentido anti apob.
MD20150091A2 (ro) Compuşi antivirali
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
IN2015DN03327A (no)
PH12014501991B1 (en) Phenicol antibacterials
PH12014502032A1 (en) Treatment of brain cancer
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF
PH12014501367A1 (en) Processes for making magnolol and derivatives thereof
PH12014501327A1 (en) Processes for making magnolol analogs
GEP201706708B (en) Isoxazolidine derivatives
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines
IN2012DE00826A (no)
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
IN2014KN02683A (no)
IN2013CH04314A (no)